BioSpace News Archive

Syneos Health®, the only fully integrated biopharmaceutical solutions organization, announced the appointment of Michelle Keefe as CEO and a member of the Company’s Board of Directors.

Merck, known as MSD outside the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy, with or without bevacizumab, for the treatment of persistent, recurrent or metastatic cervical cancer in adults whose tumors express PD-L1.

Aravive, Inc. announced the presentation of two poster abstracts at the upcoming American Society of Clinical Oncology 2022 Annual Meeting, to be held in-person on June 3-7, 2022 in Chicago, Illinois.

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 9, 2022, at 4:30 p.m. ET to report first quarter 2022 financial results and provide a corporate update.

Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2022 financial results will be reported on Wednesday, May 11, 2022 after the close of the financial markets

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD), announced today its financial results for the three months ended March 31, 2022.

Bausch Health Companies Inc. (NYSE/TSX: BHC) (“Bausch Health”) will release its first-quarter financial results on Tuesday, May 10, 2022. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to discuss the results and provide a business update.

CytoSorbents Corporation announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb™-ATR Antithrombotic Removal System for intraoperative removal of apixaban and rivaroxaban during cardiothoracic surgery.

TFF Pharmaceuticals, Inc. today announced that it will release its financial results and business update for the first quarter of 2022 on Wednesday, May 11, 2022, after the close of the U.S. financial markets.

CloudMD Software Services Inc. will release its audited financial results for the year ended December 31, 2021 on Monday, May 2, 2022, after market close.